Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 6/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | NPR3 | P17342 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701323 | 1.00 | KDM4E (0.41) | KDM4ETDP1ELANETAS1R3TAS1R1 | |
| SCHEMBL4704404 | 0.86 | KDM4E (0.46) | KDM4ETDP1EPHX2FOLH1 | |
| SCHEMBL4704408 | 0.86 | KDM4E (0.46) | KDM4ETDP1EPHX2FOLH1 | |
| SCHEMBL6210214 | 0.79 | CTSL (0.55) | — | |
| SCHEMBL4705355 | 0.79 | CTSL (0.55) | — | |
| SCHEMBL4700044 | 0.70 | TAS1R3 (0.40) | KDM4EELANETAS1R3TAS1R1CYP2C9 | |
| SCHEMBL4700048 | 0.70 | TAS1R3 (0.40) | KDM4EELANETAS1R3TAS1R1CYP2C9 | |
| SCHEMBL4703025 | 0.70 | FOLH1 (0.41) | ELANETAS1R3TAS1R1CYP2C9NPR3 | |
| SCHEMBL4703019 | 0.70 | FOLH1 (0.41) | ELANETAS1R3TAS1R1CYP2C9NPR3 | |
| SCHEMBL6509026 | 0.68 | TAS1R3 (0.46) | ELANETAS1R3TAS1R1CYP2C9NPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1372655-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-10-12 | — | — | EP | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
| EP-1372655-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002069901-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | KDM4E 2274/4885TDP1 4509/4885ELANE 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.